Skip to main content
Erschienen in: International Journal of Diabetes in Developing Countries 1/2019

19.04.2018 | Original Article

Cost of illness (COI) of type-II diabetes mellitus in Shillong, Meghalaya

verfasst von: T. Khongrangjem, Sameer Phadnis, Sumit Kumar

Erschienen in: International Journal of Diabetes in Developing Countries | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

This study aimed at contributing to the evidence base of economic burden caused due to type-II DM. The data were obtained from the 158 diabetics from the three tertiary hospitals in Shillong, Meghalaya, during January–March 2017 with the use of a semi-structured questionnaire. The information received was cross-checked with the medical records from the finance department. Patients comprised of 86 (54.4%) females and 72 (45.6%) males. The individuals under the age group of 56–65 were 49 (31%). The total median cost of illness per month was Rs. 5375 (2524–18,968) which was made up of 70.92% direct cost and 29.08% indirect cost. 58.2% respondents used their savings for getting treatment. The cost of care is high and comparable to cost in other countries. An improved understanding of COI of type-II DM will help in informing and motivating the policy and health decision makers which will reduce the national burden of this disease.
Literatur
1.
Zurück zum Zitat Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 2007;125:217–30. Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of type 2 diabetes: Indian scenario. Indian J Med Res. 2007;125:217–30.
2.
Zurück zum Zitat Huizinga MM, Rothman RL. Addressing the diabetes pandemic: a comprehensive approach. Indian J Med Res. 2006;124:481–4.PubMed Huizinga MM, Rothman RL. Addressing the diabetes pandemic: a comprehensive approach. Indian J Med Res. 2006;124:481–4.PubMed
3.
Zurück zum Zitat Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D, editor. Diabetes atlas. International Diabetes Federation. 3rd ed. Belgium: International Diabetes Federation; 2006. p. 15–103. Sicree R, Shaw J, Zimmet P. Diabetes and impaired glucose tolerance. In: Gan D, editor. Diabetes atlas. International Diabetes Federation. 3rd ed. Belgium: International Diabetes Federation; 2006. p. 15–103.
4.
Zurück zum Zitat Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.CrossRef Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53.CrossRef
6.
Zurück zum Zitat Ali MK, Narayan KM. Innovative research for equitable diabetes care in India. Diabetes Res Clin Pract. 2009;86:155–67.CrossRefPubMed Ali MK, Narayan KM. Innovative research for equitable diabetes care in India. Diabetes Res Clin Pract. 2009;86:155–67.CrossRefPubMed
8.
Zurück zum Zitat Kessler RC, Petukhova M, McInnes K, Ustün TB. Content and Scoring Rules for the WHO HPQ Absenteeism and Presenteeism Questions. Boston (MA): Harvard Medical School; 2007. Kessler RC, Petukhova M, McInnes K, Ustün TB. Content and Scoring Rules for the WHO HPQ Absenteeism and Presenteeism Questions. Boston (MA): Harvard Medical School; 2007.
9.
Zurück zum Zitat Riewpaiboon A, Chatterjee S, Piyauthakit P. Cost analysis for efficient management: diabetes treatment at a public district hospital in Thailand. Int J Pharm Pract. 2011;19:342–9.CrossRefPubMed Riewpaiboon A, Chatterjee S, Piyauthakit P. Cost analysis for efficient management: diabetes treatment at a public district hospital in Thailand. Int J Pharm Pract. 2011;19:342–9.CrossRefPubMed
11.
Zurück zum Zitat Hex N, Barlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855–62.CrossRefPubMed Hex N, Barlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855–62.CrossRefPubMed
12.
Zurück zum Zitat Barcelo A, Aedo C, Rajpathak S and Robles S. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ. 2003;81(1):19–27. Barcelo A, Aedo C, Rajpathak S and Robles S. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ. 2003;81(1):19–27.
14.
Zurück zum Zitat Henriksson F, Agardh CD, Berne C, Bolinder J, Lönnqvist F, Stenström P, et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Int Med. 2000;248(5):387–96. Henriksson F, Agardh CD, Berne C, Bolinder J, Lönnqvist F, Stenström P, et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Int Med. 2000;248(5):387–96.
16.
Zurück zum Zitat Viswanathan V, Tharkar S, Devarajan A, Kumpatla S. The socioeconomics of a developing country: a population based cost of illness study. Diab Res Clin Pract. 2010;89:334–40.CrossRef Viswanathan V, Tharkar S, Devarajan A, Kumpatla S. The socioeconomics of a developing country: a population based cost of illness study. Diab Res Clin Pract. 2010;89:334–40.CrossRef
17.
Zurück zum Zitat Anderson Carl R. Locus of control, coping and performance in a stress setting: a longitudinal study. J Appl Psychol. 1977;62:446–51. Google ScholarCrossRef Anderson Carl R. Locus of control, coping and performance in a stress setting: a longitudinal study. J Appl Psychol. 1977;62:446–51. Google ScholarCrossRef
18.
Zurück zum Zitat Narayan KM, Zhang P, Williams D, Engelau M, Imperatore G. How should developing countries manage diabetes. CMAJ. 2006;175:733–43.CrossRefPubMed Narayan KM, Zhang P, Williams D, Engelau M, Imperatore G. How should developing countries manage diabetes. CMAJ. 2006;175:733–43.CrossRefPubMed
19.
Zurück zum Zitat The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 1996;276:1409–15. The Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA 1996;276:1409–15.
20.
Zurück zum Zitat Chatterjee S, Riewpaiboon A, Piyauthakit P, Riewpaiboon W, Bonpaijit K, Panpuwong N, Acharvanuntagal V. Cost of diabetes and its complications in Thailand: A complete picture of economic burden. Health Soc Care Community. 2011;119(3):289–98. Chatterjee S, Riewpaiboon A, Piyauthakit P, Riewpaiboon W, Bonpaijit K, Panpuwong N, Acharvanuntagal V. Cost of diabetes and its complications in Thailand: A complete picture of economic burden. Health Soc Care Community. 2011;119(3):289–98.
22.
Zurück zum Zitat Dawson KG, Gomes D, Gerstein H, Blanchard JF, Kahler KH. The economic cost of diabetes in Canada, 1998. Diabetes Care. 2002;25(8):1303–7.CrossRefPubMed Dawson KG, Gomes D, Gerstein H, Blanchard JF, Kahler KH. The economic cost of diabetes in Canada, 1998. Diabetes Care. 2002;25(8):1303–7.CrossRefPubMed
23.
Zurück zum Zitat Rc E, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care. 1991;20:725–44. Rc E, Javitt JC, Herman WH, Dasbach EJ, Zbrozek AS, Dong F, et al. Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care. 1991;20:725–44.
Metadaten
Titel
Cost of illness (COI) of type-II diabetes mellitus in Shillong, Meghalaya
verfasst von
T. Khongrangjem
Sameer Phadnis
Sumit Kumar
Publikationsdatum
19.04.2018
Verlag
Springer India
Erschienen in
International Journal of Diabetes in Developing Countries / Ausgabe 1/2019
Print ISSN: 0973-3930
Elektronische ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-018-0636-z

Weitere Artikel der Ausgabe 1/2019

International Journal of Diabetes in Developing Countries 1/2019 Zur Ausgabe